Pasireotide

Overview

Pasireotide is a second-generation synthetic Somatostatin analog developed by Novartis and marketed as Signifor (subcutaneous formulation) and Signifor LAR (long-acting release intramuscular formulation). It was approved by the FDA in December 2012 for the treatment of Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative, making it the first pituitary-targeted medical therapy for this condition.

Unlike first-generation somatostatin analogs such as Octreotide and Lanreotide, which preferentially bind somatostatin receptor subtype 2 (SSTR2), pasireotide exhibits high binding affinity across multiple somatostatin receptor subtypes, particularly SSTR5. This broader receptor profile is pharmacologically significant because corticotroph adenomas in Cushing's disease predominantly express SSTR5 rather than SSTR2, making first-generation analogs ineffective for this indication.

Pasireotide is a cyclohexapeptide, meaning it contains six amino acid residues arranged in a cyclic structure. This represents a departure from the octapeptide scaffolds of octreotide and lanreotide, and the unique backbone geometry contributes to its distinct receptor binding profile.

Structure and Pharmacology

Molecular characteristics:

• Structure: Cyclic hexapeptide incorporating hydroxyproline, phenylalanine, tryptophan, lysine, tyrosine, and a modified phenylglycine
• Molecular weight: 1,047.2 Da (free base)
• Administration: Subcutaneous (0.3-0.9 mg twice daily) or intramuscular LAR (10-60 mg every 28 days)

Multi-Receptor Binding Profile

Pasireotide's binding affinities demonstrate its uniquely broad somatostatin receptor engagement:

The 40-fold higher affinity for SSTR5 compared to octreotide is the primary pharmacological basis for pasireotide's efficacy in Cushing's disease.

Mechanism of Action in Cushing's Disease

Cushing's disease is caused by an ACTH-secreting pituitary adenoma that drives excessive cortisol production from the adrenal glands. Pasireotide targets corticotroph adenoma cells through:

1. SSTR5-mediated ACTH suppression: Binding SSTR5 on corticotroph adenoma cells activates Gi-protein signaling, reducing intracellular cAMP and suppressing proopiomelanocortin (POMC) gene transcription and ACTH secretion
2. SSTR2 contribution: Secondary SSTR2-mediated inhibition provides additional suppressive effects in tumors with mixed receptor expression
3. Antiproliferative signaling: SSTR3 activation engages pro-apoptotic pathways, and SSTR1/SSTR2 activation inhibits cell proliferation via protein tyrosine phosphatase recruitment
4. Downstream cortisol reduction: Reduced ACTH secretion leads to decreased adrenal stimulation and lower circulating cortisol levels, alleviating the systemic manifestations of hypercortisolism

Clinical Applications

Cushing's Disease

In the Phase III study, patients with persistent or recurrent Cushing's disease received pasireotide 600 or 900 mcg subcutaneously twice daily for 12 months. Normalization of urinary free cortisol (UFC) was achieved in a subset of patients at both doses. Clinical improvements observed included reductions in body weight, waist circumference, blood pressure, and LDL cholesterol.

The long-acting intramuscular formulation (Signifor LAR, 10-30 mg monthly) was subsequently approved, offering improved patient convenience through monthly dosing while maintaining comparable efficacy.

Acromegaly

Signifor LAR received FDA approval in 2014 for acromegaly in patients who have had an inadequate response to surgery and/or for whom surgery is not an option. The PAOLA study demonstrated that pasireotide LAR 40 mg and 60 mg monthly achieved superior biochemical control (GH < 2.5 mcg/L and normal IGF-1) compared to continued octreotide LAR or lanreotide in patients inadequately controlled on first-generation analogs.

This superior efficacy in resistant acromegaly is attributed to pasireotide's engagement of SSTR5 and SSTR1 in addition to SSTR2, providing broader inhibitory coverage on somatotroph adenomas with heterogeneous receptor expression.

Investigational Applications

• Neuroendocrine tumors: Evaluation in somatostatin analog-refractory carcinoid tumors and pancreatic NETs
• Dumping syndrome: Post-gastrectomy symptomatic management
• Congenital hyperinsulinism: Suppression of inappropriate insulin secretion via SSTR5

Pharmacokinetics

Subcutaneous formulation:

• Tmax: 0.25-0.5 hours
• Half-life: Approximately 12 hours
• Bioavailability: High (subcutaneous)
• Protein binding: Moderate
• Metabolism: Hepatic, primarily unmetabolized excretion in bile

LAR formulation:

• Tmax: Approximately 21 days
• Effective half-life: Approximately 16 days
• Steady state: Achieved by the third monthly injection

Safety Profile

The adverse effect profile of pasireotide is consistent with broad somatostatin receptor modulation, with hyperglycemia representing the most clinically significant concern:

• Hyperglycemia: Occurs in 57-73% of patients, with new-onset diabetes in approximately 36%; driven by SSTR5-mediated suppression of insulin and incretin secretion while simultaneously reducing counter-regulatory glucagon suppression
• Gastrointestinal: Diarrhea (50-58%), nausea (18-52%), abdominal pain (16-24%)
• Cholelithiasis: 17-30%, consistent with the somatostatin analog class effect on gallbladder motility
• Hepatic: Transaminase elevations (5-10%), requiring periodic liver function monitoring
• Cardiovascular: QT prolongation observed in some patients; ECG monitoring recommended at baseline and periodically during treatment
• Injection site reactions: Pain, erythema, and swelling (subcutaneous formulation)

The high incidence and severity of hyperglycemia distinguishes pasireotide from first-generation somatostatin analogs and often requires proactive glucose management with metformin, DPP-4 inhibitors, or GLP-1 receptor agonists. The therapeutic index is narrow due to these metabolic effects. Blood glucose monitoring is essential before initiating therapy and throughout treatment.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Pasireotide (Signifor) is available in subcutaneous and long-acting release formulations. Always consult a qualified healthcare professional.

Critical safety note: Blood glucose must be monitored before and during treatment due to the high incidence of hyperglycemia (57-73%). Proactive glucose management with metformin, DPP-4 inhibitors, or GLP-1 agonists is often required. Baseline ECG and periodic QT interval monitoring are recommended. Gallbladder ultrasonography should be performed periodically.

Clinical Significance

Pasireotide represents an important advance in the pharmacological management of Cushing's disease, a condition with significant morbidity and mortality that was previously manageable only through surgery, radiation, or adrenal-targeted agents. Its development demonstrates how engineering somatostatin analogs with altered receptor selectivity profiles can unlock therapeutic applications inaccessible to first-generation compounds, advancing the drug development pipeline.

The compound also illustrates the trade-offs inherent in multi-receptor peptide pharmacology: broader target engagement can extend efficacy to new indications while simultaneously introducing mechanism-based toxicities that constrain clinical use.